GemPharmatech Co Ltd
688046
Company Profile
Business description
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
Contact
No. 12, Xuefu Road
Jiangbei New District, Jiangsu Province
Nanjing210032
CHNT: +86 2558243997
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,578
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
Expense guidance changes short-term earnings but not long-term fundamentals.
stocks
Chart of the Week: Australian asset managers face structural pressure
Read the latest take from our analysts.
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,171.10 | 72.20 | -0.78% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,763.58 | 63.33 | -0.23% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,255.76 | 102.95 | -0.19% |
| NZX 50 Index | 13,347.40 | 65.47 | -0.49% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,866.40 | 56.80 | -0.64% |
| SSE Composite Index | 4,140.18 | 11.05 | -0.27% |